Dirk Sibbing Shares a Recent ”Excellent Study” on Clopidogrel Versus Aspirin by Marco Valgimigli and Colleagues
Dirk Sibbing, Professor, Cardiologist and Angiologist at Privatklinik Lauterbacher Mühle and LMU Munich, reposted from Claudio Laudani on LinkedIn:
”Excellent study with clinically important results, especially in light of recent data at ESC 2025 in Madrid on hashtag#clopidogrel in secondary prevention for CAD patients after PCI. Valgimigli et al., Lancet 2025”
Read the full article here.
Article: Clopidogrel versus aspirin for secondary prevention of coronary artery disease: a systematic review and individual patient data meta-analysis
Auhtors: Marco Valgimigli, Ki Hong Choi, Daniele Giacoppo, Felice Gragnano, Takeshi Kimura, Hirotoshi Watanabe, Hyo-Soo Kim, Jeehoon Kang, Kyung Woo Park, Alf-Åge Pettersen, Mark Woodward, Deepak L Bhatt, Paolo Calabrò, Dominick J Angiolillo, Roxana Mehran, Young Bin Song, Joo-Yong Hahn
Claudio Laudani, Cardiovascular Disease Fellow UNICT, Post-Doc Research Scholar UFHealth JAX, shared a post on LinkedIn:
”Race has been shown to have a significant influence on clinical outcomes in patients with atherosclerotic cardiovascular disease.
However, the mechanisms behind such association are still poorly understood.
In this manuscript, we explored biological condition that may be responsible for such association, finding that among participant with atherosclerotic cardiovascular disease on chronic clopidogrel treatment, Black individuals have higher platelet reactivity (related to P2Y12 receptor activity) compared to non-Black individual.
In addition, we further confirmed the increased risk of MACE and myocardial infarction of Black individuals compared to non-black individuals among patients with coronary artery disease undergoing PCI.
These data highlight how further efforts are needed to reduce disparities between races, focusing on both healthcare access and biological process to guide the decision-making.”
Rad the full article here.
Article: Impact of Race on Profiles of Platelet Reactivity and Clinical Outcomes in Clopidogrel-Treated Participants
Authors: Luis Ortega-Paz, Cameron D. Thomas, Claudio Laudani, Salvatore Giordano, Francesco Franchi, Kayla R. Tunehag, Fabiana Rollini, Selina Durukan, Joseph S. Rossi, Maryam Farahmandsadr, George A. Stouffer, Latonya Been, Ellen C. Keeley, Julio D. Duarte, Amber L. Beitelshees, Craig R. Lee, Larisa H. Cavallari, Dominick J. Angiolillo
Stay updated on all science in the field of coagulation with Hemostasis Today.
-
Feb 16, 2026, 15:44Lakmali Silva: Silva Lab Showcases Research at the Gordon Research Conference on Plasminogen and Extracellular Proteolysis
-
Feb 16, 2026, 15:36Heghine Khachatryan: Strengthening Maternal Resilience Against Postpartum Hemorrhage
-
Feb 16, 2026, 15:34Sevak Mirabyan: Advancing Cancer Care Through Knowledge, Collaboration, and Early Diagnosis in Armenia
-
Feb 16, 2026, 15:29Chokri Ben Lamine: Key Clinical Insights of Drug Induced Thrombocytopenia
-
Feb 16, 2026, 15:28Ney Carter Borges: Coronary Intravascular Lithotripsy – Clinical Performance and Safety
-
Feb 16, 2026, 15:24Flora Peyvandi: Highlighting Overdose, Homicide, and Suicide as Causes of Maternal Death in the US
-
Feb 16, 2026, 14:53Wafaa Abougabal: Differential Diagnosis of Acute Neurologic Deficits and Stroke in PICU
-
Feb 16, 2026, 14:49Nayab Ahmed: Synthesis of ATP and Its Significance in Storage of Blood
-
Feb 16, 2026, 14:44Lukasz Kuzma: NOAC Monotherapy vs NOAC Plus Clopidogrel in AF Beyond One Year After DES